Tyzeka is a brand name of telbivudine, approved by the FDA in the following formulation(s):
TYZEKA (telbivudine - tablet; oral)
Manufacturer: NOVARTIS
Approval date: October 25, 2006
Strength(s): 600MG [RLD]
Has a generic version of Tyzeka been approved?
No. There is currently no therapeutically equivalent version of Tyzeka available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyzeka. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
&bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Patent 6,395,716
Issued: May 28, 2002
Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
Assignee(s): Novirio Pharmaceuticals Limited
Centre National da la Recherche Scientifique
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Patent expiration dates:
- August 10, 2019✓
- August 10, 2019✓
- August 10, 2019
&bgr;-L-2'-deoxy-nucleosides for the treatment of hepatitis B
Patent 6,444,652
Issued: September 3, 2002
Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
Assignee(s): Novirio Pharmaceuticals Limited
Centre National da la Recherche Scientifique
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Patent expiration dates:
- August 10, 2019✓
- August 10, 2019✓
- August 10, 2019
&bgr;-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Patent 6,566,344
Issued: May 20, 2003
Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
Assignee(s): Idenix Pharmaceuticals, Inc.
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentoftiranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Patent expiration dates:
- August 10, 2019✓
- August 10, 2019✓
- August 10, 2019
&bgr;-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B
Patent 6,569,837
Issued: May 27, 2003
Inventor(s): Gilles; Gosselin & Jean-Louis; Imbach & Martin L.; Bryant
Assignee(s): Idenix Pharmaceuticals Inc.
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Patent expiration dates:
- October 25, 2020✓
- October 25, 2020✓
- October 25, 2020
Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Patent 7,589,079
Issued: September 15, 2009
Inventor(s): Jonaitis; David & Storer; Richard
Assignee(s): Novartis AG
Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.Patent expiration dates:
- September 11, 2023✓✓✓
- September 11, 2023
β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
Patent 7,795,238
Issued: September 14, 2010
Inventor(s): Gosselin; Gilles & Imbach; Jean-Louis & Bryant; Martin L.
Assignee(s): Idenix Pharmaceuticals, Inc.
Centre National de la Recherche Scientifique
L'Université Montpellier II
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Patent expiration dates:
- August 10, 2019✓
- August 10, 2019
Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Patent 7,858,594
Issued: December 28, 2010
Inventor(s): Jonaitis; David & Storer; Richard
Assignee(s): Novartis Pharma AG
Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.Patent expiration dates:
- September 11, 2023✓✓✓
- September 11, 2023
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 25, 2011 - NEW CHEMICAL ENTITY
See also...
- Tyzeka Consumer Information (Drugs.com)
- Tyzeka Consumer Information (Wolters Kluwer)
- Tyzeka Consumer Information (Cerner Multum)
- Tyzeka Advanced Consumer Information (Micromedex)
- Tyzeka AHFS DI Monographs (ASHP)
- Telbivudine Consumer Information (Wolters Kluwer)
- Telbivudine Consumer Information (Cerner Multum)
- Telbivudine Advanced Consumer Information (Micromedex)
- Telbivudine AHFS DI Monographs (ASHP)
